OTC
IMMU

Opera Trading Capital’s Immunomedics Inc IMMU Stock Holding History

Opera Trading Capital’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,000
Closed -$18K – 132
2016
Q4 		$18K Buy
+5,000
New +$14.8K 0.01% 111

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Opera Trading Capital's IMMU Position: Q1 2017 in Review

Opera Trading Capital sold out of Immunomedics Inc (IMMU) in Q1 2017, closing a stake of 5,000 shares — an estimated $18K sold.

Opera Trading Capital first reported a position in IMMU in Q4 2016 and held it in 1 quarter. The position peaked at $18K in Q4 2016. 124 funds tracked by Wall St. Rank hold IMMU as of Q1 2017.

  • Opera Trading Capital reported no remaining Immunomedics Inc position as of Q1 2017 after selling out during the quarter.
  • Opera Trading Capital sold 5,000 Immunomedics Inc shares in Q1 2017, an estimated $18K.
  • Opera Trading Capital first reported a position in Immunomedics Inc in Q4 2016 and held it in 1 quarter.
  • Opera Trading Capital's Immunomedics Inc position peaked at $18K in Q4 2016.
  • 124 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2017.

Based on Opera Trading Capital's 13F filing for Q1 2017, filed 3 May 2017.